Zimvie [ZIMV] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Zimvie Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Zimvie Inc. wins in 5 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Zimvie Inc. Abbott Laboratories Better
P/E Ratio (TTM) -20.20 25.97 Abbott Laboratories
Price-to-Book Ratio 1.30 3.09 Zimvie Inc.
Debt-to-Equity Ratio 56.82 26.79 Abbott Laboratories
PEG Ratio 3.03 -1.41 Zimvie Inc.
EV/EBITDA 17.09 13.74 Abbott Laboratories
Profit Margin (TTM) -4.39% 13.90% Abbott Laboratories
Operating Margin (TTM) 3.33% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 3.33% 16.50% Abbott Laboratories
Return on Equity -4.76% 12.36% Abbott Laboratories
Return on Assets (TTM) 0.51% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $7.49M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 36.91% -34.98% Zimvie Inc.
Price-to-Sales Ratio (TTM) 1.21 3.57 Zimvie Inc.
Enterprise Value $699.90M $166.96B Abbott Laboratories
EV/Revenue Ratio 1.58 3.70 Zimvie Inc.
Gross Profit Margin (TTM) 64.55% N/A N/A
Revenue per Share (TTM) $16 $26 Abbott Laboratories
Earnings per Share (Diluted) $-0.69 $3.57 Abbott Laboratories
Beta (Stock Volatility) 2.06 0.78 Abbott Laboratories
Short % of Float 1.93% 1.53% Abbott Laboratories

Zimvie Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

ZIMV
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zimvie Inc.0.00%0.05%0.58%1.23%112.89%103.32%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zimvie Inc.36.91%131.59%-57.04%-57.04%-57.04%-57.04%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Zimvie Inc. vs Abbott Laboratories

MetricZIMVABT
Market Information
Market Cap i$535.72M$160.70B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i256,32613,495,583
90 Day Avg. Volume i302,28212,934,461
Last Close$18.99$88.67
52 Week Range$8.15 - $19.01$81.97 - $139.06
% from 52W High-0.11%-36.24%
All-Time High$50.40 (Feb 14, 2022)$142.60 (Dec 27, 2021)
% from All-Time High-62.32%-37.82%
Growth Metrics
Quarterly Revenue Growth0.00%0.08%
Quarterly Earnings Growth0.00%-0.19%
Financial Health
Profit Margin (TTM) i-0.04%0.14%
Operating Margin (TTM) i0.03%0.17%
Return on Equity (TTM) i-0.05%0.12%
Debt to Equity (MRQ) i56.8226.79
Cash & Liquidity
Book Value per Share (MRQ)$14.64$30.02
Cash per Share (MRQ)$2.49$5.14
Operating Cash Flow (TTM) i$11.97M$10.80B
Levered Free Cash Flow (TTM) i$11.75M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Zimvie Inc. vs Abbott Laboratories

MetricZIMV (Nov 10, 2025)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i-20.2025.97
Forward P/E i28.7715.29
PEG Ratio i3.03-1.41
Price to Sales (TTM) i1.213.57
Price to Book (MRQ) i1.303.09
Market Capitalization
Market Capitalization i$535.72M$160.70B
Enterprise Value i$699.90M$166.96B
Enterprise Value Metrics
Enterprise to Revenue i1.583.70
Enterprise to EBITDA i17.0913.74
Risk & Other Metrics
Beta i2.060.78
Book Value per Share (MRQ) i$14.64$30.02

Financial Statements Comparison: Zimvie Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricZIMV (2024)ABT (2025)
Revenue/Sales i449.75M44.33B
Cost of Goods Sold i162.30M19.32B
COGS % of Revenue i36.1%43.6%
Gross Profit i287.45M25.01B
Gross Margin i63.9%56.4%
Research & Development i26.91M2.94B
Operating Income (EBIT) i-2.10M8.05B
Operating Margin i-0.5%18.2%
EBITDA i48.17M12.03B
EBITDA Margin i10.7%27.1%
Pre-Tax Income i-23.59M8.47B
Pre-Tax Income % of Revenue i-5.2%19.1%
Income Tax i10.24M1.94B
Income Tax % of Revenue i2.3%4.4%
Net Income (Profit) i-25.83M6.52B
Profit Margin i-5.7%14.7%

Balance Sheet & Liquidity Metrics

MetricZIMV (2024)ABT (2025)
Cash & Equivalents i74.97M8.52B
Total Current Assets i257.29M26.00B
Total Current Assets % of Revenue i57.2%58.6%
Total Current Liabilities i133.94M16.50B
Total Current Liabilities % of Revenue i29.8%37.2%
Long-Term Debt i228.67M10.83B
Long-Term Debt % of Revenue i50.8%24.4%
Total Shareholders Equity i381.71M52.77B
Retained Earnings i-466.64M49.78B
Retained Earnings % of Revenue i-103.8%112.3%
Property, Plant & Equipment i017.57B

Cash Flow Statement Comparison

MetricZIMV (2024)ABT (2025)
Operating Cash Flow i33.89M10.80B
Operating Cash Flow % of Revenue i7.5%24.4%
Capital Expenditures i-6.68M-2.17B
Free Cash Flow i7.49M7.40B
FCF Margin i1.7%16.7%
Debt Repayment i-290.00M-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricZIMVABT
Shares Short i531,52523.83M
Short Ratio i0.811.93
Short % of Float i1.93%1.53%
Shares Outstanding i28.20M1.74B
Float Shares i21.66M1.73B
% Held by Insiders i2.73%0.54%
% Held by Institutions i90.96%82.23%
% Held by Public i6.31%17.23%

Dividend Analysis & Yield Comparison: Zimvie Inc. vs Abbott Laboratories

MetricZIMVABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026